Dormant proviruses are HIV's genetic blueprint silently parked inside long-lived immune cells. They are the main reason HIV has no cure: antiretroviral treatment can drive the virus to undetectable levels, but it can't clear this latent reservoir, so the virus rebounds if treatment ever stops HHS clinicalinfo.
in 2023
≈723,000 — U=U
| Item | Value |
|---|---|
| New diagnoses | 38,800 — in 2023 |
| Living with HIV | 1.12 million |
| Virally suppressed | ~65% — ≈723,000 — U=U |
| On PrEP | 381,000 |
The essentials: what a dormant provirus actually is
HIV is a virus that attacks the immune system CDC. When it infects a cell, it inserts a copy of its genes into the cell's own DNA, and that integrated copy is called a provirus. Most of those cells churn out new virus, but some go quiet and become long-lived memory cells. The provirus sits there switched off, invisible to the immune system and untouched by the drugs that block active replication.
This is the latent reservoir, and it's why an undetectable viral load isn't the same as a cure. Treatment (ART) can reduce HIV in the body to undetectable, but that controls the virus rather than eradicating it, and people who get HIV have it for life CDC ART. There is currently no effective cure. Researchers split a true cure into two goals: a sterilizing cure that rids the body of every replication-competent virus, and a functional cure where the virus persists but stays controlled without ongoing ART NIAID. Neither is available today; what we have is lifelong, highly effective treatment.
About 38,800 people were newly diagnosed with HIV in the US in 2023, and an estimated 1.12 million are living with HIV, of whom roughly 723,000 — about two-thirds — are virally suppressed CDC AtlasPlus, 2023. Diagnosis rates cluster in the South and the capital: highest in Washington DC (33 per 100,000), Georgia (26), Florida (23), and Louisiana (23).
Why the reservoir blocks a cure
ART is a combination of medicines — integrase inhibitors, NRTIs, NNRTIs, and protease inhibitors — and it works beautifully against virus that's actively copying itself. Dormant proviruses aren't copying anything, so there's nothing for the drugs to interrupt. The cells hide in tissues throughout the body and can persist for years. Stop ART and they reawaken, so an undetectable viral load depends on staying on treatment NIAID research.
A handful of people have reached lasting remission after stem-cell (bone-marrow) transplants — the Berlin patient, the London patient, and a New York woman who became the third documented case and the first woman (NIH, 2022) NIH. Those transplants were done to treat cancer or leukemia, used rare HIV-resistant CCR5-delta32 donor cells, are high-risk, and are not a scalable or generally available cure. Experimental cure strategies under study include latency-reversing 'shock and kill' approaches, gene and CCR5 editing, broadly neutralizing antibodies, and therapeutic vaccines, and none is an available cure yet. The latent reservoir remains the central barrier.
Symptoms: what HIV itself feels like
The reservoir is silent, but HIV infection has stages. Within 2 to 4 weeks after infection, about 90% of people develop flu-like symptoms — fever, chills, rash, night sweats, muscle aches, sore throat, fatigue, swollen lymph nodes, and mouth ulcers hiv.gov. This acute phase is when the viral load peaks above a million copies/mL and onward transmission is at its highest, so early symptoms after a risk are worth an urgent test.
After that comes clinical latency — the chronic stage, where the virus stays active but often causes no symptoms for a decade or more if untreated. The most severe stage, AIDS, is defined by a CD4 count under 200 cells/mm³ or an opportunistic infection (an illness that takes hold because the immune system is weakened). Early symptoms look exactly like the flu, and many people have none. Symptoms can neither confirm nor rule out HIV; only a test can do that.
Testing: the only way to know
Testing is quick. You can get a finger-stick or oral-swab rapid test with results in minutes, or a lab blood draw; testing is free at many health departments, and at-home kits exist CDC testing. Watch the window period, the gap before a test can reliably detect infection.
| Test type | Window after exposure | Sample |
|---|---|---|
| Nucleic-acid test (NAT) | 10–33 days | Lab blood draw |
| Antigen/antibody (4th-gen) lab test | 18–45 days | Lab blood draw |
| Antibody / rapid tests | 23–90 days | Finger-stick or oral swab |
A negative result is conclusive only after the window has passed with no exposure during it. If you tested too early, repeat after the window closes — see when to test after exposure for the timing, and you can get tested when you're ready. Rapid tests are convenient but detect later than lab tests, so if timing matters, read rapid hiv test vs lab test.
Treatment: control the virus, even if you can't clear it
Everyone with HIV should start ART as soon as possible after diagnosis; it's lifelong, and the goal is an undetectable viral load. Single-pill and combination options exist, and most people reach undetectable within about 6 months of starting CDC U=U. Even though treatment can't touch the dormant reservoir, it controls the active virus so completely that a 20-year-old who starts treatment before their CD4 count falls below 200 now has a life expectancy approaching that of the general population Lancet HIV.
There's a second payoff. Undetectable equals untransmittable (U=U): a person who takes HIV medicine as prescribed and stays virally suppressed does not transmit HIV to sex partners. Across PARTNER, Opposites Attract, and PARTNER2, mixed-status couples logged more than 125,000 condomless sex acts with zero linked transmissions while the positive partner was suppressed under 200 copies/mL Lancet PARTNER. So earlier hiv treatment can help prevention.
Prevention: while there's no cure, prevention is excellent
The core CDC tools are condoms, PrEP, PEP, treatment-as-prevention (U=U), and regular testing CDC. PrEP is for people without HIV who are exposed through sex or injection drug use, and it cuts HIV risk from sex by about 99% when taken as prescribed CDC PrEP.
- Daily oral PrEP: Truvada or Descovy. Descovy is not approved for people at risk through receptive vaginal sex or for people who inject drugs; Truvada covers all those routes.
- Long-acting injectable PrEP: cabotegravir (Apretude), given as two initiation doses a month apart, then every 2 months.
- PrEP needs a confirmed HIV-negative test before starting and at follow-ups (every 3 months for oral, every 2 months for injectable), plus baseline kidney, hepatitis B, and STI screening. Starting PrEP with undiagnosed HIV risks drug resistance.
- Newer options keep improving: twice-yearly injectable lenacapavir produced zero infections among women in the PURPOSE 1 trial WHO.
If you think you were just exposed, don't wait and test. Post-exposure prophylaxis must start within 72 hours and runs daily for 28 days CDC PEP; in the original occupational study it cut seroconversion by about 81%. Treat it as a same-day emergency — read up on pep for hiv and head to urgent care or an ER. Perinatal HIV is highly preventable too: with ART during pregnancy and labor plus newborn prophylaxis, mother-to-child transmission can be reduced to less than 1%.
When to see a clinician
- You had a possible exposure in the last 72 hours — go now for PEP; every hour counts.
- You have flu-like symptoms 2 to 4 weeks after a risk — ask for a test that detects early infection.
- You're HIV-negative with ongoing risk — ask about PrEP.
- You're newly diagnosed — start ART as soon as possible; earlier is better for your health and your partners.
- You're on ART — keep your visits and stay suppressed, because stopping lets the reservoir rebound.